Treatment Information

Back

Bladder Cancer treatment details. Biologic therapy.

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Survival: monthsCountry:Italy
Toxiciy Grade:3City/State/Province:Milan
Treatments:Biologic therapyHospital:Fondazione IRCCS Istituto Nazionale dei Tumori
Drugs:Journal:Link
Date:Feb 2014

Description:

Patients:
This phase 2 study involved 14 pre-treated metastatic urothelial cancer patients. The median patient age was 64 years and 13 were male.

Treatment:
Patients were treated with the biologic therapy agent called PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1 that interferes with cancer cell growth.

Toxicities:
The most severe toxicity was grade 3 thrombocytopenia. Grade 1-2 fatigue and abdominal pain were also reported.

Results:
The median overall survival was 8 months.

Support:
This study was supported by Pfizer.

Correspondence: Dr. Andrea Necchi; email: [email protected]



Back